Insys Therapeutics aims to take the rough edges off of chemo and cancer pain. The company focuses on developing drugs for treating side effects of chemotherapy, as well as therapies for pain management and other central-nervous-system conditions. Its Dronabinol candidate, a generic capsule form of Marinol awaiting FDA approval for treatment of chemotherapy-induced nausea and vomiting. In addition, its Fentanyl SL spray, delivered under the tongue for quick absorption, treats pain in cancer patients. All of the company's drug candidates are unique formulations of already-approved therapeutic ingredients. Insys acquired fellow drug-maker NeoPharm in 2010 and filed to go public in 2011.
